Morningside leads €39m series-B for biotech company Inotrem

New investor Invus and previous backers Andera Partners, Sofinnova Partners and BiomedInvest also took part in the round.

Following the deal, Morningside's Jason Dinges will join Inotrem's board of directors.

Inotrem intends to use the fresh capital to support the clinical development of its lead drug candidate, nangibotide LR12 (an anti-Trem-1 peptide), in a global multicentric phase-IIb trial in septic shock patients to deliver proof of clinical efficacy. In addition, the financing will allow Inotrem to expand its TRrem-1 franchise to address chronic inflammatory diseases.

Previous funding
Andera and Sofinnova co-led an €18m series-A round for Inotrem in March 2014. Swiss firm Biomed Invest and Inserm Transfert Initiative also took part in the investment alongside the lead backers.

Company
Established in 2013, Inotrem is a biotechnology company specialising in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a nangibotide formulation, LR12, which is a Trem-1 inhibitor designed to act as an amplifier of the immune response cycle and control unbalanced inflammatory responses. Inotrem is headquartered in Paris with a technology centre based in Nancy.

People
Morningside Ventures – Jason Dinges (partner).
Inotrem – Jean-Jacques Garaud (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Technology
• Venture
• France
• Andera Partners
• Sofinnova Partners